ORASURE TECHNOLOGIES, INC
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $115.0M | $185.8M | $405.4M | $385.0M | $233.7M | $171.7M | $154.6M | $171.3M |
| Diagnostics | — | — | $232.0M | $247.6M | $118.5M | $72.6M | $78.4M | $92.0M |
| Molecular Solutions | — | — | $173.3M | $137.4M | $115.2M | $99.2M | $76.2M | $79.3M |
| Cost of Revenue | $66.8M | $106.4M | $233.8M | $239.0M | $116.1M | $69.9M | $60.0M | $68.1M |
| Gross Profit | $48.2M | $79.4M | $171.7M | $148.4M | $117.6M | $101.9M | $94.6M | $113.6M |
| Gross Margin | 41.9% | 42.7% | 42.3% | 38.6% | 50.3% | 59.3% | 61.2% | 66.3% |
| Operating Expenses | ||||||||
| Research & Development | $42.5M | $26.0M | $33.7M | $36.2M | $34.2M | $31.0M | $19.6M | $16.3M |
| SG&A Expense | $47.7M | $46.2M | $58.2M | $68.2M | $50.3M | $42.7M | $35.3M | $38.3M |
| Operating Income | $-72.0M | $-28.3M | $32.7M | $-22.2M | $-10.2M | $-5.2M | $18.6M | $28.4M |
| Operating Margin | -62.6% | -15.2% | 8.1% | -5.8% | -4.3% | -3.0% | 12.0% | 16.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-64.6M | $-16.0M | $56.3M | $-15.7M | $-9.3M | $-3.5M | $21.3M | $31.7M |
| Income Tax Expense | $1.8M | $1.8M | $2.6M | $1.5M | $13.7M | $11.4M | $4.7M | $11.3M |
| Net Income | $-68.7M | $-19.5M | $53.7M | $-17.1M | $-23.0M | $-14.9M | $16.7M | $20.4M |
| Net Margin | -59.8% | -10.5% | 13.2% | -4.4% | -9.8% | -8.7% | 10.8% | 11.9% |
| EPS (Basic) | $-0.94 | $-0.26 | $0.73 | $-0.24 | $-0.32 | $0.22 | $0.27 | $0.33 |
| EPS (Diluted) | $-0.94 | $-0.26 | $0.72 | $-0.24 | $-0.32 | $0.22 | $0.27 | $0.33 |
| Shares Outstanding (Basic) | 73.5M | 74.4M | 73.3M | 72.5M | 72.0M | 67.5M | 61.7M | 61.1M |
| Shares Outstanding (Diluted) | 73.5M | 74.4M | 74.4M | 72.5M | 72.0M | 67.5M | 62.2M | 62.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |